Showcase SA Industry Series partner and platinum member Statewide Super is one of several companies that has invested in a COVID-19 preventative therapy, it has been revealed.
Already a long contributor to medical research investment in Australia, Statewide Super’s investment alongside other backers and the Australian Government in ENA Respiratory’s new therapy has shown early promise.
Currently known as INNA-051, it is proposed the therapy would be administered as a spray twice a week.
The results from laboratory testings with ferrets – a species preferred for trialling respiratory therapies given the similarities of their nasal system with those of humans – showed 96% effectiveness in preventing COVID-19 infection.
The potential of the therapy reducing the levels of COVID-19 in the nose and throat could have the potential to reduce transmission and prevent infections.
“South Australia has shown exceptional resilience and we are so proud that on behalf of our members, we are investing in a therapy which, based on the available positive testing results against multiple viruses, may have the potential to fight future pandemics,” says Tony D’Alessandro, Statewide Super CEO.